Redeye provides an update following Q-linea’s Q3 2025 report. Sales during the quarter came in below our expectations; however, costs were lower than anticipated, resulting in an EBIT broadly in line with our projection. We have adjusted our short-term estimates, leading to a minor revision of our fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/